The effect of methylphenidate on serum growth hormone: influence of antipsychotic drugs and diagnosis.
Intravenously administered methylphenidate, 0.5 mg/kg, causes a consistent rise in human serum growth hormone level, with peak values usually occurring 30 minutes after infusion. This rise is attenuated in patients receiving various antipsychotic medications administered on a long-term basis and is decreased in schizophrenic and drug-dependent patients. Methylphenidate causes increases in talkativeness, blood pressure, and pulse that generally parallel increases in serum growth hormone level. However, in contrast to the methylphenidate-induced rise in serum growth hormone level, methylphenidate-induced changes in cardiovascular variables and talkativeness are not altered by antipsychotic medications or diagnostic classification.
D000275:Adjustment Disorders / Q000097:blood; D000293:Adolescent; D000328:Adult; D000437:Alcoholism / Q000097:blood; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008774:Methylphenidate / Q000494:pharmacology*; D008875:Middle Aged; D011674:Pulse / Q000187:drug effects; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D019966:Substance-Related Disorders / Q000097:blood; D014705:Verbal Behavior / Q000187:drug effects
D014150:Antipsychotic Agents; D008774:Methylphenidate; D013006:Growth Hormone